Genentech/Biogen Idec Submit Rituxan sBLA For Front-Line Non-Hodgkin’s Lymphoma
Expanded indication could be approved by February 2006, contingent upon a requested priority review.
Expanded indication could be approved by February 2006, contingent upon a requested priority review.